ABCL vs ABSI

AbCellera Biologics Inc. vs Absci Corporation — Valuation Comparison 2026

ABCL

Biotechnology
AbCellera Biologics Inc.
Quality
7.3
out of 10
Value Trap
21
SAFE
Price
$5.73
Last close
Models
10/13
Active
VS

ABSI

Biotechnology
Absci Corporation
Quality
5.0
out of 10
Value Trap
29
LOW
Price
$6.08
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ABCL Fair ValueABCL Upside ABSI Fair ValueABSI Upside
Bayesian DCF Intrinsic $3.68 -35.8% $1.65 -72.9%
Earnings Power Value Intrinsic $1.35 -69.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.59 -69.1% $0.13 -97.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ABCL vs ABSI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ABCL vs ABSI — Which Stock Is More Undervalued?

ABCL scores higher with a 7.3/10 quality rating vs ABSI's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AbCellera Biologics Inc. (ABCL) and Absci Corporation (ABSI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ABCL currently trades at $5.73 with a QOC of 7.3/10, while ABSI trades at $6.08 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).